Search results for "RECTAL CANCER"

showing 10 items of 978 documents

Pelvic exenterations for primary rectal cancer: analysis from a 10-year national prospective database

2018

Aim: to identify short-term and oncologic outcomes of pelvic exenterations (PE) for locally advanced primary rectal cancer (LAPRC) in patients included in a national prospective database. Methods: few studies report on PE in patients with LAPRC. For this study, we included PE for LAPRC performed between 2006 and 2017, as available, from the Rectal Cancer Registry of the Spanish Association of Surgeons [Asociación Española de Cirujanos (AEC)]. Primary endpoints included procedure-associated complications, 5-year local recurrence (LR), disease-free survival (DFS) and overall survival (OS). A propensity-matched comparison with patients who underwent non-exenterative surgery for low rectal canc…

MaleColorectal cancerEpidemiologymedicine.medical_treatment030230 surgerycomputer.software_genre0302 clinical medicinePostoperative ComplicationsRetrospective StudieMedicineProspective StudiesOutcomeDatabaseGastroenterologyGeneral MedicineMiddle AgedColorectal surgeryTreatment OutcomeEfectes secundaris dels medicaments030220 oncology & carcinogenesisFemaleHumanAdvanced rectal cancermedicine.medical_specialtyRisk AssessmentDisease-Free SurvivalPelvis03 medical and health sciencesColorectal surgeryCàncer colorectalAdvanced rectal cancer Colorectal surgery Complication Outcome Pelvic exenterationRetrospective Cohort StudyHumansPerioperative PeriodEpidemiologiaAgedNeoplasm StagingRetrospective StudiesRectal NeoplasmPelvic exenterationbusiness.industryRectal NeoplasmsRectummedicine.diseaseColorectal cancerPelvic Exenterationbody regionsProspective StudieQuality of LifeDrug side effectsPostoperative ComplicationPelvic exenterationNeoplasm Recurrence LocalbusinessComplicationComplicationcomputer
researchProduct

A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer.

2015

Background Artesunate is an antimalarial agent with broad anti-cancer activity in in vitro and animal experiments and case reports. Artesunate has not been studied in rigorous clinical trials for anticancer effects. Aim To determine the anticancer effect and tolerability of oral artesunate in colorectal cancer (CRC). Methods This was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned for curative resection of biopsy confirmed single primary site CRC were randomised (n = 23) by computer-generated code supplied in opaque envelopes to receive preoperatively either 14 daily doses of oral artesunate (200 mg; n = 12) or placebo (n = 11). The primary outcome meas…

MaleColorectal cancerResistancelcsh:MedicineAdministration OralArtesunatePilot ProjectsPharmacologyGastroenterologyPlacebosNeutropaeniachemistry.chemical_compoundCancerlcsh:R5-920medicine.diagnostic_testGeneral MedicineImmunohistochemistryArtemisininsDihydroartemisininTreatment OutcomeTolerabilityOriginal ArticleFemalelcsh:Medicine (General)Colorectal NeoplasmsKi67medicine.medical_specialtyRandomizationPlaceboGeneral Biochemistry Genetics and Molecular BiologyDouble-Blind MethodMedian follow-upInternal medicineBiopsymedicineBiomarkers TumorHumansAgedDemographyStaining and Labelingbusiness.industrylcsh:Rmedicine.diseaseColorectal cancerSurvival AnalysisCarcinoembryonic AntigenMalariaClinical trialKi-67 AntigenchemistryArtesunateCommentarybusinessEBioMedicine
researchProduct

Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral …

2018

INTRODUCTION: The mainstay of management for locally advanced rectal cancer is chemoradiotherapy followed by surgical resection. Following chemoradiotherapy, a complete response may be detected clinically and radiologically (cCR) prior to surgery or pathologically after surgery (pCR). We aim to report the overall complete pathological response (pCR) rate and the reliability of detecting a cCR by conventional pre-operative imaging.METHODS: A pre-planned analysis of the European Society of Coloproctology (ESCP) 2017 audit was performed. Patients treated by elective rectal resection were included. A pCR was defined as a ypT0 N0 EMVI negative primary tumour; a partial response represented any r…

MaleColorectal cancerdeferral of surgery; neoadjuvant therapy; pathology; radiology; rectal cancer; Rectal surgery; surgical oncology; Gastroenterology0302 clinical medicineProspective StudiesProspective cohort studyComplete responseMedical Auditintegumentary systemIncidence (epidemiology)IncidenceRemission InductionGastroenterologyMiddle AgedMagnetic Resonance ImagingPeer reviewEuropeTreatment Outcomedeferral of surgeryResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisPreoperative Period030211 gastroenterology & hepatologyFemaleAdultmedicine.medical_specialtyRectal surgeryNO03 medical and health sciencessurgical oncologymedicineHumansneoadjuvant therapyIntensive care medicineDeferralrectal cancerPathologicalResponse Evaluation Criteria in Solid TumorsAgedNeoplasm Stagingta3126business.industryRectal NeoplasmsReproducibility of ResultsChemoradiotherapy Adjuvantmedicine.diseaseradiologyRectal Neoplasms/diagnostic imagingpathologyNeoplasm Staging/methodsbusiness
researchProduct

Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients

2014

Abstract Improved prognostic stratification of patients with TNM stage II colorectal cancer (CRC) is desired, since 20–30% of high-risk stage II patients may die within five years of diagnosis. This study was conducted to investigate REarranged during Transfection ( RET ) gene promoter CpG island methylation as a possible prognostic marker for TNM stage II CRC patients. The utility of RET promoter CpG island methylation in tumors of stage II CRC patients as a prognostic biomarker for CRC related death was studied in three independent series (including 233, 231, and 294 TNM stage II patients, respectively) by using MSP and pyrosequencing. The prognostic value of RET promoter CpG island methy…

MaleCpg island methylationOncologyCancer Researchmedicine.medical_specialtyColonColorectal cancerBiologyBioinformaticsCell Line TumorInternal medicineGeneticsmedicineHumansStage (cooking)Promoter Regions GeneticneoplasmsResearch ArticlesAgedNeoplasm StagingProportional hazards modelRectumStage II Colorectal CancerPromoterGeneral MedicineMethylationDNA MethylationMiddle AgedPrognosismedicine.diseasedigestive system diseasesOncologyDNA methylationMolecular MedicineCpG IslandsFemaleColorectal NeoplasmsMolecular Oncology
researchProduct

The association between new onset atrial fibrillation and incident cancer—A nationwide cohort study

2018

A recent analysis showed an association with new onset atrial fibrillation (NOAF) and incident cancer among women. We aimed to examine the risk of cancer among patients with NOAF in general population. A retrospective cohort of 5130 patients with NOAF was identified from a random sample of one million subjects between 2005 and 2010 from Taiwan National Health Insurance Research Database. The standard incidence ratio of incident cancer and hazard ratios were calculated by modeling cumulative incidence with competing risk of death. During a mean follow-up duration of 3.4 years, 330 patients developed cancer. The standard incidence ratio of all malignancies was 1.41 (95% confidence interval 1.…

MaleEconomicslcsh:MedicineSocial Sciences030204 cardiovascular system & hematologyVascular MedicineBrain Ischemia0302 clinical medicineRisk FactorsNeoplasmsEpidemiology of cancerAtrial FibrillationMedicine and Health SciencesGenitourinary CancersCumulative incidence030212 general & internal medicinelcsh:ScienceAged 80 and overeducation.field_of_studyMultidisciplinaryCancer Risk FactorsIncidenceHazard ratioAge FactorsMiddle AgedStrokeOncologyNeurologyFemaleArrhythmiaCohort studyResearch Articlemedicine.medical_specialtyCerebrovascular DiseasesUrologyPopulationCardiology03 medical and health sciencesBreast cancerHealth EconomicsSex FactorsDiagnostic MedicineInternal medicinemedicineCancer Detection and DiagnosisHumanseducationIschemic StrokeAgedColorectal Cancerbusiness.industrylcsh:RCancerCancers and NeoplasmsRetrospective cohort studymedicine.diseaseHealth CareWomen's Healthlcsh:QbusinessHealth InsuranceFollow-Up StudiesPLoS ONE
researchProduct

Factors associated with colorectal cancer in the context of the Mediterranean diet: a case-control study

2014

Recent evidence demonstrates that increased adherence to the Mediterranean diet (MD) may prevent colorectal cancer (CRC). The aim of this study was to evaluate the association between health-related characteristics and CRC in the context of the MD. This was a case-control study conducted on a sample of 338 consecutive patients with a first diagnosis of CRC recruited in an urban facility in the city of Catania, southern Italy, and matched with 676 apparently healthy subjects without clinical symptoms or signs of any type of cancer. Data regarding sociodemographic, clinical, and lifestyle characteristics were collected, and adherence to the Mediterranean diet pattern was assessed using the Me…

MaleGerontologyCancer Researchmedicine.medical_specialtySettore MED/09 - Medicina InternaAlcohol DrinkingMediterranean dietColorectal cancerMedicine (miscellaneous)Context (language use)Motor ActivityDiet MediterraneanRisk FactorsSurveys and QuestionnairesInternal medicinemedicineHumansFamily historySettore MED/49 - Scienze Tecniche Dietetiche ApplicateLife StyleAgedNutrition and Dieteticsmediterranean diet colorectal cancer diabetes obesity Sicilybusiness.industrySmokingCase-control studyCancerFeeding BehaviorOdds ratioMiddle Agedmedicine.diseaseObesityHealthy VolunteersLogistic ModelsItalySocioeconomic FactorsOncologyCase-Control StudiesMultivariate AnalysisPatient ComplianceFemaleColorectal Neoplasmsbusiness
researchProduct

The influence of geographical access to health care and material deprivation on colorectal cancer survival: Evidence from France and England

2014

International audience; This article investigates the influence of distance to health care and material deprivation on cancer survival for patients diagnosed with a colorectal cancer between 1997 and 2004 in France and England. This population-based study included all cases of colorectal cancer diagnosed between 1997 and 2004 in 3 cancer registries in France and 1 cancer registry in England (N=40,613). After adjustment for material deprivation, travel times in England were no longer significantly associated with survival. In France patients living between 20 and 90min from the nearest cancer unit tended to have a poorer survival, although this was not statistically significant. In England, …

MaleHealth (social science)Colorectal cancerGeography Planning and DevelopmentPopulationcolorectal cancer[SDV.CAN]Life Sciences [q-bio]/CancersurvivalHealth Services AccessibilityHealth services[SDV.CAN] Life Sciences [q-bio]/CancerHealth caremedicineHumansRegistrieseducationmaterial deprivationAgedTraveleducation.field_of_studyGeographybusiness.industrytravel timesPublic Health Environmental and Occupational HealthCancerCancer survivalMiddle Agedmedicine.diseaseHealth care accessibility3. Good healthCancer registryEnglandFemaleFranceColorectal NeoplasmsbusinessDemographyHealth & Place
researchProduct

An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesore…

2018

Introduction: Transanal total mesorectal excision (TaTME) has rapidly emerged as a novel approach for rectal cancer surgery. Safety profiles are still emerging and more comparative data is urgently needed. This study aimed to compare indications and short-term outcomes of TaTME, open, laparoscopic, and robotic TME internationally. Methods: A pre-planned analysis of the European Society of Coloproctology (ESCP) 2017 audit was performed. Patients undergoing elective total mesorectal excision (TME) for malignancy between 1 January 2017 and 15 March 2017 by any operative approach were included. The primary outcome measure was anastomotic leak. Results: Of 2579 included patients, 76.2% (1966/257…

MaleLaparoscopic surgerymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentOperative TimeAnastomosisMalignancyrectal cancer ; laparoscopic surgery ; TME ; transanal TME ; TaTME ; robotic surgery ; randomized clinical-trial ; short-term outcomes ; laparoscopic-assisted resection ; pathological outcomes ; anastomotic leakage ; initial-experience ; riskNO03 medical and health sciencesPostoperative Complications0302 clinical medicineRobotic Surgical Proceduresrobotic surgerytransanal TMEHumansMedicineRobotic surgeryProspective Studieslaparoscopic surgery; Rectal cancer; robotic surgery; TaTME; TME; transanal TME; GastroenterologyRectal cancerAgedTransanal Endoscopic Surgeryta3126Medical AuditUnivariate analysisProctectomyRectal Neoplasmsbusiness.industryRectumGastroenterologyTMEMargins of ExcisionMiddle Agedmedicine.diseaseTotal mesorectal excisionTaTMElaparoscopic surgerySurgeryTreatment OutcomeElective Surgical Procedures030220 oncology & carcinogenesisRectal cancer surgeryFemaleLaparoscopy030211 gastroenterology & hepatologybusiness
researchProduct

Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European rand…

2021

Abstract Background In colon cancer (CC), surgery remains the mainstay of treatment with curative intent. Despite several clinical trials comparing open and laparoscopic approaches, data on long-term outcomes for stage III CC are lacking. Methods This post-hoc analysis of the European PETACC8 randomized phase 3 trial included patients from 340 sites between December 2005 and November 2009, with long follow-up (median 7.56 years). Patients were randomly assigned to FOLFOX or FOLFOX+cetuximab after colonic resection. The surgical approach was left to the referring surgeon's discretion. Results Among 2555 patients included, 1796 (70.29%) were operated on by open surgery and 759 (29.71%) by lap…

MaleLaparoscopic surgerymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLeucovorinCetuximabAntineoplastic AgentsDisease-Free Survivallaw.invention03 medical and health sciences0302 clinical medicineFOLFOXRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Propensity ScoreLaparoscopyColectomyAgedNeoplasm StagingColectomyHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyPrognosismedicine.diseaseSurgeryEuropeSurvival RateClinical trialTreatment Outcome030220 oncology & carcinogenesisColonic NeoplasmsMultivariate AnalysisFemaleLaparoscopy030211 gastroenterology & hepatologyFluorouracilbusinessFollow-Up Studiesmedicine.drugDigestive and Liver Disease
researchProduct

Mutant K-ras2 in serum

2003

Mutant tumour derived DNA has been detected in the sera of colorectal cancer patients. We investigated if mutant serum KRAS2 was detectable preoperatively in a large group of patients with colorectal neoplasia. A prospective study of 94 patients who underwent putative curative resection for colorectal carcinoma (CRC) was performed to ascertain if serum mutant KRAS2 could be used postoperatively as a disease marker.Preoperative sera from 78 patients were analysed (group A). Sera from 94 patients were obtained three monthly for up to three years during the postoperative period (group B). Codon 12 and 13 KRAS2 mutations were analysed in matched tumour and serum samples.In the preoperative grou…

MaleLetterColorectal cancervirusesMutantDNA Mutational AnalysisBioinformaticsProto-Oncogene Proteins p21(ras)03 medical and health sciencesCollaborative group0302 clinical medicineProto-Oncogene ProteinsMedicineHumansRas2neoplasmsGene030304 developmental biologyAged0303 health sciencesbusiness.industryPoint mutationGastroenterologyDNA NeoplasmMiddle Agedmedicine.diseasePrognosis3. Good healthProto-Oncogene Proteins p21(ras)Molecular analysisCarcinoembryonic AntigenEpidemiologic Studies030220 oncology & carcinogenesisCancer researchras ProteinsFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsBiomarkers
researchProduct